JP2021134156A - Basal metabolism-improving composition - Google Patents

Abstract

To provide a novel basal metabolism-improving composition.SOLUTION: A basal metabolism-improving composition containing Bifidobacterium breve. It is preferable that the Bifidobacterium breve be Bifidobacterium breve MCC1274 (FERM BP-11175). It is preferable that improvement of the basal metabolism be due to increase of energy consumption in a resting state. It is preferable that the composition be a food/drink composition. It is preferable that the composition be pharmaceutical composition.SELECTED DRAWING: None

Description

The present invention relates to a composition for improving basal metabolism.

The energy required to maintain human physical function and physical activity is mainly obtained from diet. Regarding the balance between dietary energy intake and energy consumption due to maintenance of physical function and physical activity, if the intake exceeds the consumption, it causes weight gain and body fat increase, and various diseases (hyperlipidemia, hypertension, etc.) It is known that the risk of hyperlipidemia, arteriosclerosis, etc.) increases. In recent years, eating habits have diversified, and the balance of energy balance tends to lean toward energy intake. Various methods are known to consume more energy than energy intake to maintain good health.

Methods for increasing energy expenditure above intake include ingestion of low-energy diets, increased exercise opportunities and intensity, and increased basal metabolic rate. Ingestion of low-energy diets, exercise opportunities and increased intensity have the problem of being difficult to continue due to the need to change traditional lifestyles.
On the other hand, the basal metabolic rate is the minimum amount of energy metabolism necessary for living, and accounts for about 60% of the total energy consumption. If the basal metabolic rate can be increased, there is no need to change the diet or exercise. Patent Document 1 discloses an invention relating to a basal metabolism enhancer containing a lactic acid bacterium cell or a processed product thereof as an active ingredient.

JP-A-2018-95569

An object of the present invention is to provide a novel composition for improving basal metabolism.

As a result of diligent research to solve the above-mentioned problems, the present inventor has found that ingestion of Bifidobacterium breve increases resting energy consumption and improves basal metabolism.

That is, the present invention that solves the above-mentioned problems is a composition for improving basal metabolism containing Bifidobacterium breve.
The Bifidobacterium breve is preferably Bifidobacterium breve MCC1274 (FERM BP-11175).
The improvement in basal metabolism is preferably due to an increase in resting energy consumption.
The composition for improving basal metabolism is preferably a food or drink composition.
The composition for improving basal metabolism is preferably a pharmaceutical composition.

According to the present invention, it is possible to provide a novel composition for improving basal metabolism.

It is a figure which shows the result of the test example. The resting energy expenditure (kcal / h) of each group is shown.

Next, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the following preferred embodiments, and can be freely changed within the scope of the present invention. In this specification, the percentage is expressed by mass unless otherwise specified.

The composition for improving basal metabolism of the present invention contains Bifidobacterium breve.
As the Bifidobacterium breve, Bifidobacterium breve MCC1274 (FERM BP-11175) can be preferably used.
Bifidobacterium Breve MCC1274 (FERM BP-11175) is the Patent Organism Depositary Center, National Institute of Advanced Industrial Science and Technology (Japan 305-8566, Japan, 1-1-1, Higashi, Kisarazu City, Ibaraki Prefecture, Central 6th (currently IPOD Independent) NITE-IPOD, National Institute of Technology and Evaluation (NITE-IPOD): Japan, Japan, 2-5-8 Kazusakamatari, Kisarazu City, Ibaraki Prefecture, Room 120))), from August 25, 2009 It has been deposited under the accession number of IPOD FERM BP-11175 and is generally available from the storage organization.

The Bifidobacterium Breve MCC1274 (FERM BP-11175) is not limited to the deposited strain, but also includes strains substantially equivalent thereto (also referred to as “derivative strain” or “derivative strain”). That is, "Bifidobacterium Breve MCC1274 (FERM BP-11175)" is not limited to the strain itself deposited with the depositary institution with the accession number of FERM BP-11175, and there are also strains substantially equivalent thereto. Included.
Regarding the strain, "a strain substantially equivalent to the above-mentioned deposit strain" belongs to the same species as the above-mentioned deposit strain, and the similarity of the genome sequence (Average Nucleotide Identity value) with the above-mentioned deposit strain is preferably 99. A strain having 0.0% or more, more preferably 99.5% or more, still more preferably 100% identity, and preferably having the same mycological properties as the deposited strain.
The stock substantially equivalent to the deposited stock may be, for example, a derivative stock having the deposited stock as a parent stock. Derivative strains include strains bred from deposit stocks and strains naturally generated from deposit stocks.

Examples of substantially the same strains and derivative strains include the following strains.
(1) A strain determined to be the same strain as Bifidobacterium Breve MCC1274 (FERM BP-11175) by the RAPD method (Randomly Amplified Polymorphic DNA) and the PFGE method (Pulsed-field gel electrophoresis) (Probiotics in food / Health and nutritional properties and guidelines for evaluation 85 (listed on Page 43)
(2) Bifidobacterium breve Strain that carries only genes derived from MCC1274 (FERM BP-11175), does not have genes derived from foreign countries, and has a DNA identity of 95% or more. (3) Bifidobacterium. Strains bred from Breve MCC1274 (FERM BP-11175) (including strains bred by genetic engineering modification, mutation, spontaneous mutation), strains with the same trait

Bifidobacterium breve is one of the species belonging to the genus Bifidobacterium. Bifidobacterium longum subsp. Infantis (Bifidobacterium longum subsp. Infantis) is mainly found in the large intestine of infants, and among the species belonging to the genus Bifidobacterium. ) Etc., and is known as an infant-type Bifidobacterium genus bacterium.

Bifidobacterium breve can be easily grown by culturing the bacterium. Further, as the bifidobacteria brave according to the present invention, those obtained by appropriately producing and obtaining can be used, and commercially available products can also be used.
The method for culturing the Bifidobacterium breve used in the present invention is not particularly limited as long as the bacterium can grow, and the method usually used for culturing Bifidobacterium spp. Can be appropriately modified and used as necessary. .. For example, the culture temperature may be 25 to 50 ° C, preferably 30 to 40 ° C. The culture is preferably carried out under anaerobic conditions, and for example, the culture can be carried out while aerating an anaerobic gas such as carbon dioxide.

The medium for culturing the Bifidobacterium breve is not particularly limited, and a medium usually used for culturing Bifidobacterium spp. Can be appropriately modified and used as necessary. As the carbon source of the medium, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and waste sugar honey can be used depending on the assimilation property. As the nitrogen source of the medium, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride and ammonium nitrate and nitrates can be used. Further, as the inorganic salts of the medium, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used. In addition, organic components such as peptone, soybean flour, defatted soybean meal, meat extract, and yeast extract may be used in the medium. Further, as the medium, a known medium may be prepared and used, and as the medium, for example, MRS medium can be preferably used as the prepared medium.

Bifidobacterium breve can use the cells themselves, cultures of the cells, or processed products of the cells. The bacterial cells are usually preferably contained in a form containing live bacterial cells, but are not particularly limited. The bacterial cell may be, for example, a live bacterial cell, a dead bacterial cell, or a mixture of a live bacterial cell and a dead bacterial cell.
As the culture of the cells, for example, the culture obtained by the culture may be used as it is, the culture may be diluted or concentrated and used, or the cells recovered from the culture may be used. Moreover, you may use culture supernatant or culture fraction as a culture.
As the processed product of the bacterial cells, crushing, heating, freeze-drying, and dilutions, dried products or fractions thereof can be used for the bacterial cells or the culture.

The compositions of the present invention can increase resting energy expenditure and, as a result, improve basal metabolism. In the present specification, "resting" means a case where high-intensity exercise such as sports is not particularly performed, and activities in daily life (sitting, lying down, sleeping, standing, walking, climbing stairs, etc.) are performed. Means if
In the present specification, the “resting energy consumption” means, for example, the energy consumption per hour (kcal / h) calculated by the variant (1) of Weir in the test example described later.
As used herein, the term "basal metabolism" means energy metabolism due to physiologically performed activities (breathing, body temperature maintenance, etc.) in order to maintain physical activity.

The content of Bifidobacterium breve, the culture of the bacterium, and the processed product of the bacterium in the composition of the present invention is not particularly limited, but for example, the amount of bacterial cells of the bacterium is 1.0 per 1 mL of the composition. It is preferably × 10 ⁴ cfu or more, and more preferably 2.0 × 10 ⁷ cfu or more. In addition, cfu refers to a colony forming unit. In the present specification, for example, it can be the value when cultivated at 38 ° C. in a solid medium containing 10% by mass of reduced skim milk powder. In addition, when the cells are dead cells, CFU can be replaced with individual cells (cells).
These may usually be in the range of content when distributed as an oral composition.

The subject to which the composition of the present invention is administered (administrator) and the subject to be ingested (ingestor) are not particularly limited as long as they are animals, but are usually humans. In addition, it may be any of adults, children, infants, newborns (including low-weight babies), etc., but it is usually an adult. The gender is not particularly limited.
The subject to which the composition of the present invention is administered (administrator) and the subject to be ingested (ingestor) are not particularly limited as long as they need to improve basal metabolism or increase resting energy consumption.
In addition, it is generally known that by improving basal metabolism, body temperature rises and physical functions such as blood circulation are improved. Therefore, the subject to which the composition of the present invention is administered (administrator) and the subject to be ingested (ingestor) may be a person with poor circulation and hypothermia.

The ingestion (administration) timing of the composition of the present invention is not particularly limited, and can be appropriately selected according to the state of the ingestion (administration) target.

The ingestion (administration) amount of the composition of the present invention is appropriately selected depending on the age, gender, condition, other conditions, etc. of the ingestion (administration) subject.
The intake (administration) amount of the composition of the present invention is preferably in the range of 0.5 to 5 g / day for adults, for example, as the intake (administration) amount of the bacterial cells of Bifidobacterium breve according to the present invention. The range of 1 to 4 g / day is more preferable, and 2 to 3 g / day is even more preferable.
The composition of the present invention can be ingested (administered) once or in a plurality of times a day regardless of the amount and duration of ingestion (administration).

The ingestion (administration) period of the composition of the present invention is not particularly limited. In addition, there is no particular upper limit on the intake (administration) period, and continuous and long-term intake (administration) is possible.

The route of ingestion (administration) of the composition of the present invention may be oral or parenteral, but oral is preferable. In addition, parenteral ingestion (administration) includes transdermal, intravenous injection, rectal administration, inhalation and the like.

When the composition of the present invention is to be orally ingested (administered), it is preferably in the form of food and drink.

The morphology and properties of the food and drink are not particularly limited as long as they can be orally ingested (administered) without impairing the effects of the present invention, and the bacterium of the genus Bifidobacterium, the culture of the bacterium, and the treated product of the bacterium are not particularly limited. It can be produced by a usual method using raw materials usually used for foods and drinks, except that one or two or more kinds selected from the above are contained.

Foods and drinks may be in the form of liquid, paste, gel solid, powder, etc., for example, nutritional supplements (supplements), tablets; liquid foods (nutrient foods for tube intake); bread, macaroni, spaghetti. , Noodles, cake mix, fried flour, bread flour and other wheat flour products; instant noodles, cup noodles, retort / cooked foods, canned cooking, microwave foods, instant soups / stews, instant miso soups / soups, canned soups, freeze-dried foods , Other instant foods such as instant foods; canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, processed agricultural products such as cereals (processed grain products); canned marine products, fish hams and sausages , Seafood paste products, fishery delicacies, boiled fish and other marine products; canned livestock and pastes, processed livestock products such as meat ham and sausage; , Prepared milk powder, cream, other dairy products such as dairy products; butter, margarines, vegetable oils and other fats and oils; soy sauce, miso, sauces, tomato processing seasonings, mirins, vinegars, etc. Ingredients: Combined seasonings / foods such as cooking mixes, curry bases, sauces, dressings, noodles, spices, and other complex seasonings; Frozen foods; caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, jelly, and other confectionery; carbonated beverages, natural fruit juice , Fruit juice drinks, soft drinks with fruit juice, fruit meat drinks, fruit drinks with fruit grains, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powder drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, etc. Favorite beverages such as favorite beverages, baby foods, sprinkles, other commercially available foods such as Ochazuke paste; prepared powdered milk for childcare; enteral nutritional foods; functional foods (foods for specified health use, nutritionally functional foods), etc. ..

It can also be used as feed as one aspect of food and drink. Examples of the feed include pet food, livestock feed, fish feed and the like.
The form of the feed is not particularly limited, and in addition to one or more selected from the Bifidobacterium spp., The culture of the bacteria, and the processed product of the bacteria, for example, corn, wheat, barley, rye, etc. Grains such as mylo; Vegetable oil cakes such as soybean oil cake, rapeseed oil cake, palm oil cake, and flaxseed oil cake; Animal feeds such as fish flour, defatted milk powder, casein, yellow grease, and tallow; yeasts such as torula yeast and beer yeast; mineral feeds such as calcium tertiary phosphate and calcium carbonate; fats and oils; single amino acids; containing sugars, etc. It may be something to do.

When the composition of the present invention is in the form of a food or drink (including feed), it can be provided and sold as a food or drink indicating an application for improving basal metabolism or an increase in energy consumption at rest. be.

Such "display" act includes all acts for informing the consumer of the use, and if it is an expression that can recall or analogize the use, the purpose of the display, the content of the display, etc. Regardless of the object or medium to be displayed, all of them fall under the act of "displaying" in the present invention.
Further, it is preferable that the "display" is performed by an expression that allows the consumer to directly recognize the application. Specifically, the act of transferring a product related to food and drink or the packaging of the product with the above-mentioned use, displaying it for delivery, transfer or delivery, and importing it, advertising on the product, price list or transaction documents Examples include the act of describing the above-mentioned use and displaying or distributing it, or describing the above-mentioned use in the information containing these and providing it by an electromagnetic (Internet, etc.) method.

On the other hand, as the display content, it is preferable that the display is approved by the government or the like (for example, a display obtained based on various systems established by the government and performed in a manner based on such approval). In addition, it is preferable to attach such display contents to packaging, containers, catalogs, pamphlets, promotional materials such as POPs at sales sites, and other documents.

In addition, "labeling" includes health foods, functional foods, enteral nutrition foods, special purpose foods, health functional foods, specified health foods, nutritional functional foods, functionally labeled foods, non-medicinal products, etc. The display is also mentioned. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, a system related to foods for specified health use, nutritionally functional foods, or functionally labeled foods, or labeling approved by a system similar to these, and the like can be mentioned. Specifically, labeling as a food for specified health use, labeling as a food for specified health use with conditions, labeling to the effect that it affects the structure and function of the body, labeling for reducing the risk of illness, and functionality based on scientific evidence. Indications, etc. can be mentioned, and more specifically, the Cabinet Office Ordinance on Permits for Special Use Indications, etc. stipulated in the Health Promotion Act (August 31, 2001 Cabinet Office Ordinance No. 57) Labeling as food for specified health use (particularly labeling for health use) and similar labeling specified in the above are typical examples.

Such indications include, for example, "for those who want to increase basal metabolism", "improve metabolism", "increase energy consumption", "for those who are concerned about a decrease in basal metabolism", and "hypothermia". "For those who become cold", "For those who are worried about coldness" and so on.

The composition of the present invention can also be in the form of a pharmaceutical product.
The route of ingestion (administration) of the drug may be oral or parenteral, but oral is preferable. In addition, parenteral ingestion (administration) includes transdermal, intravenous injection, rectal administration, inhalation and the like.
As the form of the drug, it can be appropriately formulated into a desired dosage form according to the ingestion (administration) method. For example, in the case of oral ingestion (administration), it can be formulated into a solid preparation such as a powder, a granule, a tablet, or a capsule; a liquid preparation such as a solution, a syrup, a suspension, or an emulsion. In the case of parenteral ingestion (administration), it can be formulated into a suppository, an ointment, an injection, or the like.
At the time of formulation, components such as excipients, pH adjusters, colorants, and flavoring agents that are usually used for formulation can be used. It is also possible to use other medicines such as other medicinal ingredients and ingredients having a known or future basal metabolism improving effect.
In addition, the formulation can be carried out by a known method as appropriate depending on the dosage form. At the time of formulation, a carrier usually used for formulation may be blended and formulated as appropriate. Examples of such carriers include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents and the like.

Examples of excipients include sugar derivatives such as lactose, sucrose, glucose, mannit, and sorbit; starch derivatives such as corn starch, horse bell starch, α-starch, dextrin, and carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, and the like. Cellulous derivatives such as hydroxypropylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium; gum arabic; dextran; purulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonic acid Carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate can be mentioned.

Examples of the binder include gelatin; polyvinylpyrrolidone; macrogol, etc., in addition to the above-mentioned excipient.

Examples of the disintegrant include, in addition to the above-mentioned excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium, and crosslinked polyvinylpyrrolidone.

Examples of the lubricant include talc; stearic acid; metal stearic acid salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and gay wax; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid. Sodium carboxylic acid salts such as sodium benzoate; Sulfates such as sodium sulfate; Leucine; Lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; Be done.

Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic acid anhydride; and sorbic acid.

Examples of the flavoring agent include sweeteners, acidulants, and flavors.
Examples of the carrier used in the case of a liquid preparation for oral ingestion (administration) include a solvent such as water.

The timing of ingesting (administering) the drug of the present invention is not particularly limited, for example, before meals, after meals, between meals, and before bedtime.

The present invention will be described in more detail below with reference to the test examples, but the present invention is not limited to these test examples.

<Test example>
(1) Purpose This test example was conducted to confirm the effect on resting energy consumption when ingesting Bifidobacterium breve.
(2) Sample preparation A lyophilized powder of Bifidobacterium Breve MCC1274 (accession number FERM BP-11175, available from NITE-IPOD) ^{was diluted with physiological saline to a concentration of 1 × 10 9} CFU / mL. , As a test sample.
In addition, physiological saline was used as a control sample.

(3) Test method 7-week-old C57BL / 6J mice (Charles River Laboratories, Japan: healthy mice) were allowed to freely ingest lab MR stock feed (manufactured by Norsan Industries) and tap water, and were acclimatized for 1 week.
After that, 12 mice were grouped into two groups, a bifidobacteria breve administration group (also referred to as a test sample group) and a physiological saline administration group (also referred to as a control sample group), and bred separately. It was bred using a gauge. Each mouse was continuously administered with each sample once a day using an oral sonde for 3 weeks. The test sample was administered at 1 ml, 1 × 10 ⁹ CFU / day / animal, and the control sample was administered at 10 ml / kg body weight / day / animal.
_{Oxygen intake (VO 2} , ml / min) and carbon dioxide emissions during the mouse activity period (8 pm to 8 am) using a breath gas measuring device (AT1100A, manufactured by Anima Co., Ltd.) 3 weeks after the start of intake. (VCO ₂ , ml / min) was continuously measured. The resting energy consumption (REE) was calculated by the following Weir variant (1) based on the references.
REE (kcal / h) = [3.9 × (VO ₂ , mL / min) + 1.1 × (VCO ₂ , mL / min)] × 1.44 / 24 (hours) ・ ・ ・ (1)
References: WEIR, JBDB New methods for calculating metabolic rate with special reference to protein metabolism. J. Physiol. 1949, 109, 1-9.

(4) Test results The test results are shown in FIG. The resting energy expenditure (REE) of the saline-administered group (control sample group) was 0.53 kcal / h, whereas the REE of the bifidobacteria-breve-administered group (test sample group) was 0. It was 58 kcal / h (Fig. 1). Resting energy expenditure was significantly increased in the Bifidobacterium breve group compared with the saline group (Student's t-test: **: p <0.01).
From the above, it was found that Bifidobacterium Breve MCC1274 (FERM BP-11175) has an effect of improving basal metabolism.

Claims (5)

A composition for improving basal metabolism containing Bifidobacterium breve. The composition according to claim 1, wherein the Bifidobacterium breve is Bifidobacterium bleve MCC1274 (FERM BP-11175). The composition according to claim 1 or 2, wherein the improvement in basal metabolism is due to an increase in energy consumption at rest. The composition according to any one of claims 1 to 3, which is a food and drink composition. The composition for use according to any one of claims 1 to 3, which is a pharmaceutical composition.

Images